Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

MASOUD M AZIZAD

Allopathic & Osteopathic Physicians Internal Medicine

NPI
1033174826
CMS profile
183370
Location
NORTHRIDGE, CA

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2023 · Entire year

$2,218.47

107 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2023 · entire year · sorted by reported total

Nature of paymentAmountRecords
Food and Beverage $2,218.47 107

By paying entity

PY2023 · entire year · sorted by reported total

Page 2 of 3; records 51–100 of 107 matching records. This page contains 50 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

MASOUD M AZIZAD

NPI 1033174826 · CMS profile ID 183370

Allopathic & Osteopathic Physicians / Internal Medicine

NORTHRIDGE, CA

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2023; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 2 of 3; records 51–100 of 107 matching records. This page contains 50 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1033174826?year=2023&recipient=provider&page=2#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/fb3a65aa-c901-4a38-a813-b04b00dfa2a9

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
MASOUD M AZIZAD, NPI 1033174826, CMS profile ID 183370. General Payments, PY2023; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 2 of 3; records 51–100 of 107 matching records. This page contains 50 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1033174826?year=2023&recipient=provider&page=2#records-h. Source: https://openpaymentsdata.cms.gov/dataset/fb3a65aa-c901-4a38-a813-b04b00dfa2a9.
APA 7
IndustryPayments. (2026). MASOUD M AZIZAD, NPI 1033174826, CMS profile ID 183370. General Payments, PY2023; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 2 of 3; records 51–100 of 107 matching records. This page contains 50 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1033174826?year=2023&recipient=provider&page=2#records-h. Source: https://openpaymentsdata.cms.gov/dataset/fb3a65aa-c901-4a38-a813-b04b00dfa2a9.
Bluebook
MASOUD M AZIZAD, NPI 1033174826, CMS profile ID 183370, IndustryPayments, General Payments, PY2023; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 2 of 3; records 51–100 of 107 matching records. This page contains 50 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/fb3a65aa-c901-4a38-a813-b04b00dfa2a9. https://industrypayments.org/provider/npi-1033174826?year=2023&recipient=provider&page=2#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2023

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2023 · Physicians and non-physician practitioners · CMS publication 2026-06-30

107 matching records · $2,218.47 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 107 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 51–100 of 107.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
Lilly USA, LLC $16.0407/14/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1031812295 CMS
Daiichi Sankyo Inc. $17.1307/11/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1006437775 CMS
GlaxoSmithKline, LLC. $30.8706/30/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1001058479 CMS
Regeneron Healthcare Solutions, Inc. $24.2306/30/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 999083243 CMS
Galderma Laboratories, L.P. $21.8606/29/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1059679527 CMS
AbbVie Inc. $17.3306/21/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 996183385 CMS
Abbott Laboratories $20.9306/20/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1018537989 CMS
Daiichi Sankyo Inc. $24.3806/20/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1006459055 CMS
Lilly USA, LLC $6.3206/16/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1031812289 CMS
Boehringer Ingelheim Pharmaceuticals, Inc. $27.1406/14/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 996611137 CMS
Amgen Inc. $25.5606/12/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1020634673 CMS
Daiichi Sankyo Inc. $24.3806/06/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1006459063 CMS
AbbVie Inc. $33.8606/03/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 996183383 CMS
Lilly USA, LLC $7.7706/02/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1031809479 CMS
Lilly USA, LLC $31.3005/22/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1031839937 CMS
AbbVie Inc. $8.4605/17/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 996183381 CMS
Daiichi Sankyo Inc. $23.8305/16/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1006440015 CMS
Regeneron Healthcare Solutions, Inc. $22.1105/12/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 999083239 CMS
Janssen Pharmaceuticals, Inc $27.2505/11/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 987755987 CMS
AbbVie Inc. $18.2405/05/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 996183379 CMS
Amgen Inc. $18.1805/01/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1020634671 CMS
Daiichi Sankyo Inc. $21.9104/27/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1006404007 CMS
Abbott Laboratories $17.6104/26/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1018541101 CMS
Lilly USA, LLC $7.4504/24/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1031890295 CMS
AbbVie Inc. $23.1804/21/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 996183377 CMS
Lilly USA, LLC $4.8704/17/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1031809475 CMS
Lucid Diagnostics Inc. $20.5104/12/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1057652015 CMS
AbbVie Inc. $22.5104/07/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 996183375 CMS
Regeneron Healthcare Solutions, Inc. $16.5603/29/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 999083235 CMS
Ironwood Pharmaceuticals, Inc $16.0203/27/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1045556477 CMS
AbbVie Inc. $22.3803/25/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 996183373 CMS
AbbVie Inc. $5.2303/24/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 996183371 CMS
Amgen Inc. $24.3603/20/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1020634669 CMS
AbbVie Inc. $8.1703/17/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 996183369 CMS
AbbVie Inc. $17.6203/15/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 996183367 CMS
Abbott Laboratories $18.5803/13/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1018525081 CMS
Daiichi Sankyo Inc. $26.0503/10/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1006342743 CMS
Regeneron Healthcare Solutions, Inc. $31.8502/23/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 999083229 CMS
AbbVie Inc. $9.2402/22/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 996183365 CMS
Lilly USA, LLC $5.6202/20/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1031864281 CMS
AbbVie Inc. $5.2102/17/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 996183363 CMS
Lilly USA, LLC $16.0802/15/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1031890283 CMS
AbbVie Inc. $21.5202/04/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 996183361 CMS
AbbVie Inc. $8.4702/03/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 996183359 CMS
Boehringer Ingelheim Pharmaceuticals, Inc. $23.4402/01/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 996611141 CMS
Ironwood Pharmaceuticals, Inc $14.0101/30/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1045567877 CMS
Lilly USA, LLC $11.4801/30/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1031890291 CMS
Regeneron Healthcare Solutions, Inc. $25.1601/30/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 999083225 CMS
Lilly USA, LLC $23.4401/28/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1031890287 CMS
Abbott Laboratories $20.8201/27/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1018526577 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $1,879.19 119
PY2020 $2,038.95 115
PY2021 $2,053.84 115
PY2022 $2,320.87 127
PY2023 $2,218.47 107
PY2024 $2,689.77 110
PY2025 $2,849.53 124

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Principal investigator $1,501,735.50 276
PY2024 Recipient $1,876.00 1
PY2024 Principal investigator $2,072,364.33 91
PY2023 Recipient $4,147.58 1
PY2023 Principal investigator $1,852,343.80 53
PY2022 Recipient $9,644.00 1
PY2022 Principal investigator $2,485,525.48 54
PY2021 Recipient $2,995.53 1
PY2021 Principal investigator $9,996,231.35 100
PY2020 Principal investigator $2,408,536.67 140
PY2019 Principal investigator $777,399.83 96

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2025

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

276 records in PY2025

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 Merck Sharp & Dohme LLC $20,020.56 12/31/2025 Non-covered Recipient Entity
Valley Clinical Trials, Inc.
A Phase 3, Randomized, Placebo-Controlled, Double Blind Clinical Study to Evaluate the Efficacy and Safety of Molnupiravir MK-4482 in Non-Hospitalized Adults with COVID-19 at High Risk for Disease Progression No dispute reported 06/30/2026 1232929585
Principal investigator 1 Merck Sharp & Dohme LLC $274.40 12/31/2025 Non-covered Recipient Entity
Valley Clinical Trials, Inc.
A Phase 3, Randomized, Placebo-Controlled, Double Blind Clinical Study to Evaluate the Efficacy and Safety of Molnupiravir MK-4482 in Non-Hospitalized Adults with COVID-19 at High Risk for Disease Progression No dispute reported 06/30/2026 1232929587
Principal investigator 1 Merck Sharp & Dohme LLC $0.58 12/31/2025 Non-covered Recipient Entity
Valley Clinical Trials Inc.
A Phase 3, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Safety, Tolerability, and Immunogenicity of the Concomitant Administration of Either 23-Valent Pneumococcal Polysaccharide Vaccine or 15-Valent Pneumococcal Conjugate Vaccine wi No dispute reported 06/30/2026 1232933138
Principal investigator 1 Merck Sharp & Dohme LLC $159.25 12/31/2025 Non-covered Recipient Entity
Valley Clinical Trials Inc.
A Phase 3, Multicenter, Open-Label Study to Evaluate the Safety and Immunogenicity of 2-dose Regimens of 9vHPV and mRNA-1273 SARS-CoV-2 Vaccines Where the First Dose of Each Vaccine Are Given Concomitantly in Boys and Girls 9 to 11 Years of Age No dispute reported 06/30/2026 1232933210
Principal investigator 1 Merck Sharp & Dohme LLC $55,309.34 12/31/2025 Non-covered Recipient Entity
Valley Clinical Trials Inc.
A Phase 3, International, Multi-center, Randomized, Double-blind, Placebo-controlled Clinical Trial to Study the Efficacy, Immunogenicity, and Safety of the 9vHPV Vaccine, a Multivalent L1 Virus-like Particle Vaccine, in the prevention of oral persistent No dispute reported 06/30/2026 1232933618
Principal investigator 1 Alnylam Pharmaceuticals Inc. $3,290.00 12/17/2025 Non-covered Recipient Entity
Valley Clinical Trials, Inc - Northridge - Flourish - PPDS
Zilebesiran as Add-on Therapy in Patients With High Cardiovascular Risk and Hypertension Not Adequately Controlled by Standard of Care Antihypertensive Medications (KARDIA-3) No dispute reported 06/30/2026 1215513643
Principal investigator 1 Boehringer Ingelheim International GmbH $547.50 12/17/2025 Non-covered Recipient Entity
Valley Clinical Trials
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220785089
Principal investigator 1 Boehringer Ingelheim International GmbH $19.14 12/17/2025 Non-covered Recipient Entity
Valley Clinical Trials
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220785091
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $1,044.60 12/16/2025 Non-covered Recipient Entity
Valley Clinical Trials
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220817918
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $16,047.00 12/16/2025 Non-covered Recipient Entity
Valley Clinical Trials
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220817920
Principal investigator 1 Janssen Research & Development, LLC $3,477.00 12/15/2025 Non-covered Recipient Entity
Vly Clnc Trials
A Study of Milvexian in Participants After a Recent Acute Coronary Syndrome (LIBREXIA-ACS) No dispute reported 06/30/2026 1175174207
Principal investigator 1 Merck Sharp & Dohme LLC $79,337.83 12/15/2025 Non-covered Recipient Entity
Valley Clinical Trials Inc.
A Phase 3, International, Multi-center, Randomized, Double-blind, Placebo-controlled Clinical Trial to Study the Efficacy, Immunogenicity, and Safety of the 9vHPV Vaccine, a Multivalent L1 Virus-like Particle Vaccine, in the prevention of oral persistent No dispute reported 06/30/2026 1232933616
Principal investigator 1 Janssen Research & Development, LLC $6,881.00 12/12/2025 Non-covered Recipient Entity
Vly Clnc Trials
A Phase 3, Randomized, Double-Blind, Double-Dummy, Parallel Group, Active Controlled Study to Evaluate the Efficacy and Safety of Milvexian, an Oral Factor XIa Inhibitor, Versus Apixaban in Participants with Atrial Fibrillation No dispute reported 06/30/2026 1175174686
Principal investigator 1 Janssen Research & Development, LLC $200.00 12/12/2025 Non-covered Recipient Entity
VALLEY CLINICAL TRIALS INC
A Non-Interventional Survey Study on the Preferences of Patients with Atrial Fibrillation and Physicians Treating Atrial Fibrillation for Anticoagulant Treatment Outcomes No dispute reported 06/30/2026 1175346355
Principal investigator 1 Alnylam Pharmaceuticals Inc. $627.20 12/10/2025 Non-covered Recipient Entity
Valley Clinical Trials, Inc - Northridge - Flourish - PPDS
Zilebesiran as Add-on Therapy in Patients With High Cardiovascular Risk and Hypertension Not Adequately Controlled by Standard of Care Antihypertensive Medications (KARDIA-3) No dispute reported 06/30/2026 1215513667
Principal investigator 1 Merck Sharp & Dohme LLC $73,488.66 12/10/2025 Non-covered Recipient Entity
Valley Clinical Trials, Inc.
A Phase 3, Randomized, Placebo-Controlled, Double Blind Clinical Study to Evaluate the Efficacy and Safety of Molnupiravir MK-4482 in Non-Hospitalized Adults with COVID-19 at High Risk for Disease Progression No dispute reported 06/30/2026 1232929583
Principal investigator 1 Alnylam Pharmaceuticals Inc. $2,000.00 12/03/2025 Non-covered Recipient Entity
Valley Clinical Trials, Inc - Northridge - Flourish - PPDS
A Phase 3 Global, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Zilebesiran in Addition to Standard of Care in Reducing Major Adverse Cardiovascular Events in Adult Patients with Hypertension Not Adequately Controlled and With Either Established Cardiovascular Disease or High Risk for Cardiovascular Disease No dispute reported 06/30/2026 1215513610
Principal investigator 1 Alnylam Pharmaceuticals Inc. $20,895.00 12/03/2025 Non-covered Recipient Entity
Valley Clinical Trials, Inc - Northridge - Flourish - PPDS
A Phase 3 Global, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Zilebesiran in Addition to Standard of Care in Reducing Major Adverse Cardiovascular Events in Adult Patients with Hypertension Not Adequately Controlled and With Either Established Cardiovascular Disease or High Risk for Cardiovascular Disease No dispute reported 06/30/2026 1215513613
Principal investigator 1 Alnylam Pharmaceuticals Inc. $2,750.00 12/03/2025 Non-covered Recipient Entity
Valley Clinical Trials, Inc - Northridge - Flourish - PPDS
A Phase 3 Global, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Zilebesiran in Addition to Standard of Care in Reducing Major Adverse Cardiovascular Events in Adult Patients with Hypertension Not Adequately Controlled and With Either Established Cardiovascular Disease or High Risk for Cardiovascular Disease No dispute reported 06/30/2026 1215513617
Principal investigator 1 Alnylam Pharmaceuticals Inc. $3,377.00 12/03/2025 Non-covered Recipient Entity
Valley Clinical Trials, Inc - Northridge - Flourish - PPDS
A Phase 3 Global, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Zilebesiran in Addition to Standard of Care in Reducing Major Adverse Cardiovascular Events in Adult Patients with Hypertension Not Adequately Controlled and With Either Established Cardiovascular Disease or High Risk for Cardiovascular Disease No dispute reported 06/30/2026 1215513623
Principal investigator 1 Alnylam Pharmaceuticals Inc. $266.00 12/03/2025 Non-covered Recipient Entity
Valley Clinical Trials, Inc - Northridge - Flourish - PPDS
Zilebesiran as Add-on Therapy in Patients With High Cardiovascular Risk and Hypertension Not Adequately Controlled by Standard of Care Antihypertensive Medications (KARDIA-3) No dispute reported 06/30/2026 1215513655
Principal investigator 1 Alnylam Pharmaceuticals Inc. $119.00 12/03/2025 Non-covered Recipient Entity
Valley Clinical Trials, Inc - Northridge - Flourish - PPDS
Zilebesiran as Add-on Therapy in Patients With High Cardiovascular Risk and Hypertension Not Adequately Controlled by Standard of Care Antihypertensive Medications (KARDIA-3) No dispute reported 06/30/2026 1215513659
Principal investigator 1 AstraZeneca Pharmaceuticals LP $15,382.60 12/03/2025 Non-covered Recipient Entity
VALLEY CLINICAL TRIALS
A Phase III, Randomised, Double-blind, Placebo-controlled, Parallel-group Study to Assess the Effect of AZD0780 on Major Adverse Cardiovascular Events in Patients with Established Atherosclerotic Cardiovascular Disease (ASCVD) or at High Risk for a First ASCVD Event No dispute reported 06/30/2026 1185537151
Principal investigator 1 Alnylam Pharmaceuticals Inc. $579.60 12/01/2025 Non-covered Recipient Entity
Valley Clinical Trials, Inc - Northridge - Flourish - PPDS
Zilebesiran as Add-on Therapy in Patients With High Cardiovascular Risk and Hypertension Not Adequately Controlled by Standard of Care Antihypertensive Medications (KARDIA-3) No dispute reported 06/30/2026 1215513639
Principal investigator 1 Boehringer Ingelheim International GmbH $47.50 12/01/2025 Non-covered Recipient Entity
Valley Clinical Trials
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220785067
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 12/01/2025 Non-covered Recipient Entity
Valley Clinical Trials
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220785069
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 12/01/2025 Non-covered Recipient Entity
Valley Clinical Trials
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220785071
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 12/01/2025 Non-covered Recipient Entity
Valley Clinical Trials
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220785073
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 12/01/2025 Non-covered Recipient Entity
Valley Clinical Trials
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220785075
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 12/01/2025 Non-covered Recipient Entity
Valley Clinical Trials
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220785077
Principal investigator 1 Janssen Research & Development, LLC $1,696.00 11/21/2025 Non-covered Recipient Entity
Vly Clnc Trials
A Study of Milvexian in Participants After a Recent Acute Coronary Syndrome (LIBREXIA-ACS) No dispute reported 06/30/2026 1175174631
Principal investigator 1 Janssen Research & Development, LLC $13,688.00 11/19/2025 Non-covered Recipient Entity
Vly Clnc Trials
A Phase 3, Randomized, Double-Blind, Double-Dummy, Parallel Group, Active Controlled Study to Evaluate the Efficacy and Safety of Milvexian, an Oral Factor XIa Inhibitor, Versus Apixaban in Participants with Atrial Fibrillation No dispute reported 06/30/2026 1175174662
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $23,219.10 11/14/2025 Non-covered Recipient Entity
Valley Clinical Trials
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220817914
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $3,826.67 11/14/2025 Non-covered Recipient Entity
Valley Clinical Trials
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220817916
Principal investigator 1 Alnylam Pharmaceuticals Inc. $500.00 11/12/2025 Non-covered Recipient Entity
Valley Clinical Trials, Inc - Northridge - Flourish - PPDS
Zilebesiran as Add-on Therapy in Patients With High Cardiovascular Risk and Hypertension Not Adequately Controlled by Standard of Care Antihypertensive Medications (KARDIA-3) No dispute reported 06/30/2026 1215513646
Principal investigator 1 Alnylam Pharmaceuticals Inc. $60.00 11/12/2025 Non-covered Recipient Entity
Valley Clinical Trials, Inc - Northridge - Flourish - PPDS
Zilebesiran as Add-on Therapy in Patients With High Cardiovascular Risk and Hypertension Not Adequately Controlled by Standard of Care Antihypertensive Medications (KARDIA-3) No dispute reported 06/30/2026 1215513650
Principal investigator 1 ModernaTX, Inc. $500.00 11/12/2025 Non-covered Recipient Entity
VALLEY CLINICAL TRIALS INC
A Study of mRNA-1010 Compared With a Licensed Influenza Vaccine in Adults ?50 Years of Age No dispute reported 06/30/2026 1253010180
Principal investigator 1 Janssen Research & Development, LLC $8,190.00 11/07/2025 Non-covered Recipient Entity
Vly Clnc Trials
A Phase 3, Randomized, Double-Blind, Double-Dummy, Parallel Group, Active Controlled Study to Evaluate the Efficacy and Safety of Milvexian, an Oral Factor XIa Inhibitor, Versus Apixaban in Participants with Atrial Fibrillation No dispute reported 06/30/2026 1175174551
Principal investigator 1 Alnylam Pharmaceuticals Inc. $266.00 11/03/2025 Non-covered Recipient Entity
Valley Clinical Trials, Inc - Northridge - Flourish - PPDS
Zilebesiran as Add-on Therapy in Patients With High Cardiovascular Risk and Hypertension Not Adequately Controlled by Standard of Care Antihypertensive Medications (KARDIA-3) No dispute reported 06/30/2026 1215513662
Principal investigator 1 Janssen Research & Development, LLC $1,246.00 11/03/2025 Non-covered Recipient Entity
Vly Clnc Trials
A Phase 3, Randomized, Double-Blind, Double-Dummy, Parallel Group, Active Controlled Study to Evaluate the Efficacy and Safety of Milvexian, an Oral Factor XIa Inhibitor, Versus Apixaban in Participants with Atrial Fibrillation No dispute reported 06/30/2026 1175174202
Principal investigator 1 Boehringer Ingelheim International GmbH $49.88 11/01/2025 Non-covered Recipient Entity
Valley Clinical Trials
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220785051
Principal investigator 1 Boehringer Ingelheim International GmbH $86.00 11/01/2025 Non-covered Recipient Entity
Valley Clinical Trials
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220785053
Principal investigator 1 Boehringer Ingelheim International GmbH $47.50 11/01/2025 Non-covered Recipient Entity
Valley Clinical Trials
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220785055
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 11/01/2025 Non-covered Recipient Entity
Valley Clinical Trials
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220785057
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 11/01/2025 Non-covered Recipient Entity
Valley Clinical Trials
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220785059
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 11/01/2025 Non-covered Recipient Entity
Valley Clinical Trials
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220785061
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 11/01/2025 Non-covered Recipient Entity
Valley Clinical Trials
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220785063
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 11/01/2025 Non-covered Recipient Entity
Valley Clinical Trials
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220785065
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $400.00 10/29/2025 Non-covered Recipient Entity
Valley Clinical Trials
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220817908
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $1,785.60 10/29/2025 Non-covered Recipient Entity
Valley Clinical Trials
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220817910
Principal investigator 1 Boehringer Ingelheim International GmbH $39.96 10/27/2025 Non-covered Recipient Entity
Valley Clinical Trials
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220785079
Principal investigator 1 Boehringer Ingelheim International GmbH $182.50 10/27/2025 Non-covered Recipient Entity
Valley Clinical Trials
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220785081
Principal investigator 1 Boehringer Ingelheim International GmbH $442.20 10/27/2025 Non-covered Recipient Entity
Valley Clinical Trials
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220785083
Principal investigator 1 Boehringer Ingelheim International GmbH $8.70 10/27/2025 Non-covered Recipient Entity
Valley Clinical Trials
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220785085
Principal investigator 1 Boehringer Ingelheim International GmbH $5.52 10/27/2025 Non-covered Recipient Entity
Valley Clinical Trials
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220785087
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $1,200.00 10/23/2025 Non-covered Recipient Entity
Valley Clinical Trials
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220817906
Principal investigator 1 Alnylam Pharmaceuticals Inc. $902.65 10/22/2025 Non-covered Recipient Entity
Valley Clinical Trials, Inc - Northridge - Flourish - PPDS
Zilebesiran as Add-on Therapy in Patients With High Cardiovascular Risk and Hypertension Not Adequately Controlled by Standard of Care Antihypertensive Medications (KARDIA-3) No dispute reported 06/30/2026 1215513634
Principal investigator 1 Janssen Research & Development, LLC $3,859.00 10/22/2025 Non-covered Recipient Entity
Vly Clnc Trials
A Study of Milvexian in Participants After a Recent Acute Coronary Syndrome (LIBREXIA-ACS) No dispute reported 06/30/2026 1175174489
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $5,899.00 10/20/2025 Non-covered Recipient Entity
Valley Clinical Trials
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220817912
Principal investigator 1 Alnylam Pharmaceuticals Inc. $1,212.40 10/17/2025 Non-covered Recipient Entity
Valley Clinical Trials, Inc - Northridge - Flourish - PPDS
Zilebesiran as Add-on Therapy in Patients With High Cardiovascular Risk and Hypertension Not Adequately Controlled by Standard of Care Antihypertensive Medications (KARDIA-3) No dispute reported 06/30/2026 1215513631
Principal investigator 1 Janssen Research & Development, LLC $1,743.00 10/17/2025 Non-covered Recipient Entity
Vly Clnc Trials
A Phase 3, Randomized, Double-Blind, Double-Dummy, Parallel Group, Active Controlled Study to Evaluate the Efficacy and Safety of Milvexian, an Oral Factor XIa Inhibitor, Versus Apixaban in Participants with Atrial Fibrillation No dispute reported 06/30/2026 1175174711
Principal investigator 1 AstraZeneca Pharmaceuticals LP $23,125.00 10/15/2025 Non-covered Recipient Entity
VALLEY CLINICAL TRIALS INC.
A Phase III, Randomised, Double-blind, Placebo-controlled, Parallel-group Study to Assess the Effect of AZD0780 on Major Adverse Cardiovascular Events in Patients with Established Atherosclerotic Cardiovascular Disease (ASCVD) or at High Risk for a First ASCVD Event No dispute reported 06/30/2026 1185537149
Principal investigator 1 Janssen Research & Development, LLC $7.25 10/13/2025 Non-covered Recipient Entity
VALLEY CLINICAL TRIALS INC
A Non-Interventional Survey Study on the Preferences of Patients with Atrial Fibrillation and Physicians Treating Atrial Fibrillation for Anticoagulant Treatment Outcomes No dispute reported 06/30/2026 1175346305
Principal investigator 1 Janssen Research & Development, LLC $27.00 10/13/2025 Non-covered Recipient Entity
VALLEY CLINICAL TRIALS INC
A Non-Interventional Survey Study on the Preferences of Patients with Atrial Fibrillation and Physicians Treating Atrial Fibrillation for Anticoagulant Treatment Outcomes No dispute reported 06/30/2026 1175346312
Principal investigator 1 Janssen Research & Development, LLC $7.79 10/13/2025 Non-covered Recipient Entity
VALLEY CLINICAL TRIALS INC
A Non-Interventional Survey Study on the Preferences of Patients with Atrial Fibrillation and Physicians Treating Atrial Fibrillation for Anticoagulant Treatment Outcomes No dispute reported 06/30/2026 1175346326
Principal investigator 1 Janssen Research & Development, LLC $2.03 10/13/2025 Non-covered Recipient Entity
VALLEY CLINICAL TRIALS INC
A Non-Interventional Survey Study on the Preferences of Patients with Atrial Fibrillation and Physicians Treating Atrial Fibrillation for Anticoagulant Treatment Outcomes No dispute reported 06/30/2026 1175346334
Principal investigator 1 Janssen Research & Development, LLC $2,350.00 10/09/2025 Non-covered Recipient Entity
Vly Clnc Trials
A Study of Milvexian in Participants After a Recent Acute Coronary Syndrome (LIBREXIA-ACS) No dispute reported 06/30/2026 1175174246
Principal investigator 1 Boehringer Ingelheim International GmbH $47.50 10/01/2025 Non-covered Recipient Entity
Valley Clinical Trials
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220785039
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 10/01/2025 Non-covered Recipient Entity
Valley Clinical Trials
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220785041
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 10/01/2025 Non-covered Recipient Entity
Valley Clinical Trials
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220785043
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 10/01/2025 Non-covered Recipient Entity
Valley Clinical Trials
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220785045
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 10/01/2025 Non-covered Recipient Entity
Valley Clinical Trials
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220785047
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 10/01/2025 Non-covered Recipient Entity
Valley Clinical Trials
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220785049
Principal investigator 1 Alnylam Pharmaceuticals Inc. $266.00 09/26/2025 Non-covered Recipient Entity
Valley Clinical Trials, Inc - Northridge - Flourish - PPDS
Zilebesiran as Add-on Therapy in Patients With High Cardiovascular Risk and Hypertension Not Adequately Controlled by Standard of Care Antihypertensive Medications (KARDIA-3) No dispute reported 06/30/2026 1215513507
Principal investigator 1 Alnylam Pharmaceuticals Inc. $180.00 09/26/2025 Non-covered Recipient Entity
Valley Clinical Trials, Inc - Northridge - Flourish - PPDS
Zilebesiran as Add-on Therapy in Patients With High Cardiovascular Risk and Hypertension Not Adequately Controlled by Standard of Care Antihypertensive Medications (KARDIA-3) No dispute reported 06/30/2026 1215513512
Principal investigator 1 Alnylam Pharmaceuticals Inc. $500.00 09/24/2025 Non-covered Recipient Entity
Valley Clinical Trials, Inc - Northridge - Flourish - PPDS
Zilebesiran as Add-on Therapy in Patients With High Cardiovascular Risk and Hypertension Not Adequately Controlled by Standard of Care Antihypertensive Medications (KARDIA-3) No dispute reported 06/30/2026 1215513503
Principal investigator 1 Boehringer Ingelheim International GmbH $328.50 09/24/2025 Non-covered Recipient Entity
Valley Clinical Trials
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220785035
Principal investigator 1 Boehringer Ingelheim International GmbH $13.92 09/24/2025 Non-covered Recipient Entity
Valley Clinical Trials
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220785037
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $2,511.00 09/24/2025 Non-covered Recipient Entity
Valley Clinical Trials
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220817896
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $334.00 09/24/2025 Non-covered Recipient Entity
Valley Clinical Trials
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220817898
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $400.00 09/24/2025 Non-covered Recipient Entity
Valley Clinical Trials
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220817900
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $500.00 09/24/2025 Non-covered Recipient Entity
Valley Clinical Trials
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220817902
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $1,344.00 09/24/2025 Non-covered Recipient Entity
Valley Clinical Trials
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220817904
Principal investigator 1 Janssen Research & Development, LLC $1,743.00 09/24/2025 Non-covered Recipient Entity
Vly Clinic Trials
A Phase 3, Randomized, Double-Blind, Double-Dummy, Parallel Group, Active Controlled Study to Evaluate the Efficacy and Safety of Milvexian, an Oral Factor XIa Inhibitor, Versus Apixaban in Participants with Atrial Fibrillation No dispute reported 06/30/2026 1175174403
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $400.00 09/22/2025 Non-covered Recipient Entity
Valley Clinical Trials
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220817894
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $9,274.50 09/19/2025 Non-covered Recipient Entity
Valley Clinical Trials
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220817892
Principal investigator 1 Janssen Research & Development, LLC $13,161.00 09/19/2025 Non-covered Recipient Entity
Vly Clinic Trials
A Phase 3, Randomized, Double-Blind, Double-Dummy, Parallel Group, Active Controlled Study to Evaluate the Efficacy and Safety of Milvexian, an Oral Factor XIa Inhibitor, Versus Apixaban in Participants with Atrial Fibrillation No dispute reported 06/30/2026 1175174646
Principal investigator 1 Janssen Research & Development, LLC $2,212.00 09/19/2025 Non-covered Recipient Entity
Vly Clinic Trials
A Study of Milvexian in Participants After a Recent Acute Coronary Syndrome (LIBREXIA-ACS) No dispute reported 06/30/2026 1175174744
Principal investigator 1 Alnylam Pharmaceuticals Inc. $500.00 09/17/2025 Non-covered Recipient Entity
Valley Clinical Trials, Inc - Northridge - Flourish - PPDS
Zilebesiran as Add-on Therapy in Patients With High Cardiovascular Risk and Hypertension Not Adequately Controlled by Standard of Care Antihypertensive Medications (KARDIA-3) No dispute reported 06/30/2026 1215513516
Principal investigator 1 Alnylam Pharmaceuticals Inc. $8,691.70 09/17/2025 Non-covered Recipient Entity
Valley Clinical Trials, Inc - Northridge - Flourish - PPDS
Zilebesiran as Add-on Therapy in Patients With High Cardiovascular Risk and Hypertension Not Adequately Controlled by Standard of Care Antihypertensive Medications (KARDIA-3) No dispute reported 06/30/2026 1215513520
Principal investigator 1 Alnylam Pharmaceuticals Inc. $2,980.25 09/17/2025 Non-covered Recipient Entity
Valley Clinical Trials, Inc - Northridge - Flourish - PPDS
Zilebesiran as Add-on Therapy in Patients With High Cardiovascular Risk and Hypertension Not Adequately Controlled by Standard of Care Antihypertensive Medications (KARDIA-3) No dispute reported 06/30/2026 1215513529
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $400.00 09/11/2025 Non-covered Recipient Entity
Valley Clinical Trials
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220817888
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $269.00 09/11/2025 Non-covered Recipient Entity
Valley Clinical Trials
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220817890
Principal investigator 1 Amgen Inc. $12,341.64 09/09/2025 Non-covered Recipient Entity
VALLEY CLINICAL TRIALS, INC.
A Phase 3 Randomized, Double-blind, Placebo-controlled Study to Evaluate the Impact of Maridebart Cafraglutide on Cardiovascular Outcomes in Participants With Atherosclerotic Cardiovascular Disease and Overweight or Obesity No dispute reported 06/30/2026 1246651148
Principal investigator 1 Boehringer Ingelheim International GmbH $30.79 09/01/2025 Non-covered Recipient Entity
Valley Clinical Trials
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220784989
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 09/01/2025 Non-covered Recipient Entity
Valley Clinical Trials
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220785001
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 09/01/2025 Non-covered Recipient Entity
Valley Clinical Trials
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220785003
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 09/01/2025 Non-covered Recipient Entity
Valley Clinical Trials
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220785005
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 09/01/2025 Non-covered Recipient Entity
Valley Clinical Trials
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220785007
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 09/01/2025 Non-covered Recipient Entity
Valley Clinical Trials
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220785009
Principal investigator 1 Boehringer Ingelheim International GmbH $47.50 09/01/2025 Non-covered Recipient Entity
Valley Clinical Trials
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220785025
Principal investigator 1 Janssen Research & Development, LLC $1,165.00 08/29/2025 Non-covered Recipient Entity
VALLEY CLINICAL TRIALS INC
A Non-Interventional Survey Study on the Preferences of Patients with Atrial Fibrillation and Physicians Treating Atrial Fibrillation for Anticoagulant Treatment Outcomes No dispute reported 06/30/2026 1175346319
Principal investigator 1 ModernaTX, Inc. $79.04 08/28/2025 Non-covered Recipient Entity
VALLEY CLINICAL TRIALS INC
A Study of mRNA-1010 Compared With a Licensed Influenza Vaccine in Adults ?50 Years of Age No dispute reported 06/30/2026 1253010200
Principal investigator 1 Janssen Research & Development, LLC $201.00 08/25/2025 Non-covered Recipient Entity
Vly Clinic Trials
A Study of Milvexian in Participants After a Recent Acute Coronary Syndrome (LIBREXIA-ACS) No dispute reported 06/30/2026 1175174637
Principal investigator 1 Janssen Research & Development, LLC $14,900.00 08/25/2025 Non-covered Recipient Entity
Vly Clinic Trials
A Phase 3, Randomized, Double-Blind, Double-Dummy, Parallel Group, Active Controlled Study to Evaluate the Efficacy and Safety of Milvexian, an Oral Factor XIa Inhibitor, Versus Apixaban in Participants with Atrial Fibrillation No dispute reported 06/30/2026 1175174678
Principal investigator 1 Janssen Research & Development, LLC $2,695.00 08/13/2025 Non-covered Recipient Entity
Vly Clinic Trials
A Phase 3, Randomized, Double-Blind, Double-Dummy, Parallel Group, Active Controlled Study to Evaluate the Efficacy and Safety of Milvexian, an Oral Factor XIa Inhibitor, Versus Apixaban in Participants with Atrial Fibrillation No dispute reported 06/30/2026 1175174543
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $30,726.90 08/08/2025 Non-covered Recipient Entity
Valley Clinical Trials
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220817886
Principal investigator 1 Amgen Inc. $158,102.50 08/01/2025 Non-covered Recipient Entity
VALLEY CLINICAL TRIALS, INC.
A Phase 3 Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy, Safety, and Tolerability of Maridebart Cafraglutide in Adult Participants With Type 2 Diabetes Mellitus Who Have Obesity or Are Overweight (MARITIME-2) No dispute reported 06/30/2026 1246651144
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 08/01/2025 Non-covered Recipient Entity
Valley Clinical Trials
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220784991
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 08/01/2025 Non-covered Recipient Entity
Valley Clinical Trials
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220784993
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 08/01/2025 Non-covered Recipient Entity
Valley Clinical Trials
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220784995
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 08/01/2025 Non-covered Recipient Entity
Valley Clinical Trials
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220784997
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 08/01/2025 Non-covered Recipient Entity
Valley Clinical Trials
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220784999
Principal investigator 1 Boehringer Ingelheim International GmbH $47.50 08/01/2025 Non-covered Recipient Entity
Valley Clinical Trials
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220785023
Principal investigator 1 Boehringer Ingelheim International GmbH $547.50 07/28/2025 Non-covered Recipient Entity
Valley Clinical Trials
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220785027
Principal investigator 1 Boehringer Ingelheim International GmbH $552.75 07/28/2025 Non-covered Recipient Entity
Valley Clinical Trials
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220785029
Principal investigator 1 Boehringer Ingelheim International GmbH $37.50 07/28/2025 Non-covered Recipient Entity
Valley Clinical Trials
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220785031
Principal investigator 1 Boehringer Ingelheim International GmbH $8.70 07/28/2025 Non-covered Recipient Entity
Valley Clinical Trials
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220785033
Principal investigator 1 Janssen Research & Development, LLC $9,463.00 07/23/2025 Non-covered Recipient Entity
Vly Clinic Trials
A Phase 3, Randomized, Double-Blind, Double-Dummy, Parallel Group, Active Controlled Study to Evaluate the Efficacy and Safety of Milvexian, an Oral Factor XIa Inhibitor, Versus Apixaban in Participants with Atrial Fibrillation No dispute reported 06/30/2026 1175174337
Principal investigator 1 Janssen Research & Development, LLC $674.00 07/23/2025 Non-covered Recipient Entity
Vly Clinic Trials
A Study of Milvexian in Participants After a Recent Acute Coronary Syndrome (LIBREXIA-ACS) No dispute reported 06/30/2026 1175174751
Principal investigator 1 ModernaTX, Inc. $830.13 07/23/2025 Non-covered Recipient Entity
VALLEY CLINICAL TRIALS INC
A Study of mRNA-1010 Compared With a Licensed Influenza Vaccine in Adults ?50 Years of Age No dispute reported 06/30/2026 1253010182
Principal investigator 1 Janssen Research & Development, LLC $792.00 07/21/2025 Non-covered Recipient Entity
VALLEY CLINICAL TRIALS INC
A Non-Interventional Survey Study on the Preferences of Patients with Atrial Fibrillation and Physicians Treating Atrial Fibrillation for Anticoagulant Treatment Outcomes No dispute reported 06/30/2026 1175346364
Principal investigator 1 Alnylam Pharmaceuticals Inc. $1,212.40 07/16/2025 Non-covered Recipient Entity
Valley Clinical Trials, Inc - Northridge - Flourish - PPDS
Zilebesiran as Add-on Therapy in Patients With High Cardiovascular Risk and Hypertension Not Adequately Controlled by Standard of Care Antihypertensive Medications (KARDIA-3) No dispute reported 06/30/2026 1215513525
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 07/01/2025 Non-covered Recipient Entity
Valley Clinical Trials
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220785011
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 07/01/2025 Non-covered Recipient Entity
Valley Clinical Trials
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220785013
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 07/01/2025 Non-covered Recipient Entity
Valley Clinical Trials
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220785015
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 07/01/2025 Non-covered Recipient Entity
Valley Clinical Trials
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220785017
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 07/01/2025 Non-covered Recipient Entity
Valley Clinical Trials
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220785019
Principal investigator 1 Boehringer Ingelheim International GmbH $47.50 07/01/2025 Non-covered Recipient Entity
Valley Clinical Trials
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220785021
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $35,856.00 06/26/2025 Non-covered Recipient Entity
Valley Clinical Trials
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220817884
Principal investigator 1 Janssen Research & Development, LLC $3,795.00 06/26/2025 Non-covered Recipient Entity
Vly Clinic Trials
A Phase 3, Randomized, Double-Blind, Double-Dummy, Parallel Group, Active Controlled Study to Evaluate the Efficacy and Safety of Milvexian, an Oral Factor XIa Inhibitor, Versus Apixaban in Participants with Atrial Fibrillation No dispute reported 06/30/2026 1175174417
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $456.00 06/25/2025 Non-covered Recipient Entity
Valley Clinical Trials
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220817880
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $216.00 06/25/2025 Non-covered Recipient Entity
Valley Clinical Trials
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220817882
Principal investigator 1 Boehringer Ingelheim International GmbH $46.64 06/24/2025 Non-covered Recipient Entity
Valley Clinical Trials
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220784985
Principal investigator 1 Boehringer Ingelheim International GmbH $36.50 06/24/2025 Non-covered Recipient Entity
Valley Clinical Trials
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220784987
Principal investigator 1 Janssen Research & Development, LLC $1,872.00 06/23/2025 Non-covered Recipient Entity
Vly Clinic Trials
A Phase 3, Randomized, Double-Blind, Double-Dummy, Parallel Group, Active Controlled Study to Evaluate the Efficacy and Safety of Milvexian, an Oral Factor XIa Inhibitor, Versus Apixaban in Participants with Atrial Fibrillation No dispute reported 06/30/2026 1175174669
Principal investigator 1 Janssen Research & Development, LLC $1,139.00 06/20/2025 Non-covered Recipient Entity
Vly Clinic Trials
A Study of Milvexian in Participants After a Recent Acute Coronary Syndrome (LIBREXIA-ACS) No dispute reported 06/30/2026 1175174496
Principal investigator 1 Janssen Research & Development, LLC $12,175.00 06/20/2025 Non-covered Recipient Entity
Vly Clinic Trials
A Phase 3, Randomized, Double-Blind, Double-Dummy, Parallel Group, Active Controlled Study to Evaluate the Efficacy and Safety of Milvexian, an Oral Factor XIa Inhibitor, Versus Apixaban in Participants with Atrial Fibrillation No dispute reported 06/30/2026 1175174796
Principal investigator 1 ModernaTX, Inc. $22,188.98 06/18/2025 Non-covered Recipient Entity
VALLEY CLINICAL TRIALS INC
A Study of mRNA-1010 Compared With a Licensed Influenza Vaccine in Adults ?50 Years of Age No dispute reported 06/30/2026 1253010192
Principal investigator 1 Janssen Research & Development, LLC $3,506.00 06/13/2025 Non-covered Recipient Entity
VALLEY CLINICAL TRIALS INC
A Non-Interventional Survey Study on the Preferences of Patients with Atrial Fibrillation and Physicians Treating Atrial Fibrillation for Anticoagulant Treatment Outcomes No dispute reported 06/30/2026 1175346349
Principal investigator 1 Janssen Research & Development, LLC $2,634.00 06/12/2025 Non-covered Recipient Entity
VALLEY CLINICAL TRIALS INC
A Non-Interventional Survey Study on the Preferences of Patients with Atrial Fibrillation and Physicians Treating Atrial Fibrillation for Anticoagulant Treatment Outcomes No dispute reported 06/30/2026 1175346342
Principal investigator 1 ModernaTX, Inc. $4,149.60 06/04/2025 Non-covered Recipient Entity
VALLEY CLINICAL TRIALS INC
A Study of mRNA-1010 Compared With a Licensed Influenza Vaccine in Adults ?50 Years of Age No dispute reported 06/30/2026 1253010174
Principal investigator 1 ModernaTX, Inc. $830.13 06/04/2025 Non-covered Recipient Entity
VALLEY CLINICAL TRIALS INC
A Study of mRNA-1010 Compared With a Licensed Influenza Vaccine in Adults ?50 Years of Age No dispute reported 06/30/2026 1253010176
Principal investigator 1 ModernaTX, Inc. $296.40 06/04/2025 Non-covered Recipient Entity
VALLEY CLINICAL TRIALS INC
A Study of mRNA-1010 Compared With a Licensed Influenza Vaccine in Adults ?50 Years of Age No dispute reported 06/30/2026 1253010218
Principal investigator 1 Boehringer Ingelheim International GmbH $47.50 06/01/2025 Non-covered Recipient Entity
Valley Clinical Trials
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220784963
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 06/01/2025 Non-covered Recipient Entity
Valley Clinical Trials
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220784965
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 06/01/2025 Non-covered Recipient Entity
Valley Clinical Trials
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220784967
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 06/01/2025 Non-covered Recipient Entity
Valley Clinical Trials
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220784969
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 06/01/2025 Non-covered Recipient Entity
Valley Clinical Trials
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220784971
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 06/01/2025 Non-covered Recipient Entity
Valley Clinical Trials
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220784973
Principal investigator 1 ModernaTX, Inc. $17,532.00 05/28/2025 Non-covered Recipient Entity
VALLEY CLINICAL TRIALS INC
A Study of mRNA-1010 Compared With a Licensed Influenza Vaccine in Adults ?50 Years of Age No dispute reported 06/30/2026 1253010188
Principal investigator 1 ModernaTX, Inc. $42,703.32 05/28/2025 Non-covered Recipient Entity
VALLEY CLINICAL TRIALS INC
A Study of mRNA-1010 Compared With a Licensed Influenza Vaccine in Adults ?50 Years of Age No dispute reported 06/30/2026 1253010198
Principal investigator 1 ModernaTX, Inc. $16,697.20 05/28/2025 Non-covered Recipient Entity
VALLEY CLINICAL TRIALS INC
A Study of mRNA-1010 Compared With a Licensed Influenza Vaccine in Adults ?50 Years of Age No dispute reported 06/30/2026 1253010204
Principal investigator 1 Boehringer Ingelheim International GmbH $23.32 05/27/2025 Non-covered Recipient Entity
Valley Clinical Trials
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220784977
Principal investigator 1 Boehringer Ingelheim International GmbH $949.00 05/27/2025 Non-covered Recipient Entity
Valley Clinical Trials
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220784979
Principal investigator 1 Boehringer Ingelheim International GmbH $530.64 05/27/2025 Non-covered Recipient Entity
Valley Clinical Trials
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220784981
Principal investigator 1 Boehringer Ingelheim International GmbH $34.80 05/27/2025 Non-covered Recipient Entity
Valley Clinical Trials
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220784983
Principal investigator 1 Janssen Research & Development, LLC $12,492.00 05/21/2025 Non-covered Recipient Entity
Vly Clinic Trials
A Phase 3, Randomized, Double-Blind, Double-Dummy, Parallel Group, Active Controlled Study to Evaluate the Efficacy and Safety of Milvexian, an Oral Factor XIa Inhibitor, Versus Apixaban in Participants with Atrial Fibrillation No dispute reported 06/30/2026 1175174352
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $76.00 05/15/2025 Non-covered Recipient Entity
Valley Clinical Trials
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220817878
Principal investigator 1 ModernaTX, Inc. $4,980.78 05/15/2025 Non-covered Recipient Entity
VALLEY CLINICAL TRIALS INC
A Study of mRNA-1010 Compared With a Licensed Influenza Vaccine in Adults ?50 Years of Age No dispute reported 06/30/2026 1253010196
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $16,289.10 05/13/2025 Non-covered Recipient Entity
Valley Clinical Trials
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220817876
Principal investigator 1 Alnylam Pharmaceuticals Inc. $120.00 05/07/2025 Non-covered Recipient Entity
Valley Clinical Trials, Inc - Northridge - Flourish - PPDS
Zilebesiran as Add-on Therapy in Patients With High Cardiovascular Risk and Hypertension Not Adequately Controlled by Standard of Care Antihypertensive Medications (KARDIA-3) No dispute reported 06/30/2026 1215513468
Principal investigator 1 Alnylam Pharmaceuticals Inc. $500.00 05/07/2025 Non-covered Recipient Entity
Valley Clinical Trials, Inc - Northridge - Flourish - PPDS
Zilebesiran as Add-on Therapy in Patients With High Cardiovascular Risk and Hypertension Not Adequately Controlled by Standard of Care Antihypertensive Medications (KARDIA-3) No dispute reported 06/30/2026 1215513475
Principal investigator 1 Boehringer Ingelheim International GmbH $47.50 05/01/2025 Non-covered Recipient Entity
Valley Clinical Trials
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220784949
Principal investigator 1 Boehringer Ingelheim International GmbH $86.00 05/01/2025 Non-covered Recipient Entity
Valley Clinical Trials
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220784951
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 05/01/2025 Non-covered Recipient Entity
Valley Clinical Trials
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220784953
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 05/01/2025 Non-covered Recipient Entity
Valley Clinical Trials
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220784955
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 05/01/2025 Non-covered Recipient Entity
Valley Clinical Trials
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220784957
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 05/01/2025 Non-covered Recipient Entity
Valley Clinical Trials
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220784959
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 05/01/2025 Non-covered Recipient Entity
Valley Clinical Trials
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220784961
Principal investigator 1 Eli Lilly and Company $192.34 04/30/2025 Non-covered Recipient Entity
VALLEY CLINICAL TRIALS INC
A STUDY OF LY3556050 IN ADULT PARTICIPANTS WITH DIABETIC PERIPHERAL NEUROPATHIC PAIN No dispute reported 06/30/2026 1187890994
Principal investigator 1 ModernaTX, Inc. $6,698.56 04/28/2025 Non-covered Recipient Entity
VALLEY CLINICAL TRIALS INC
A Study of mRNA-1010 Compared With a Licensed Influenza Vaccine in Adults ?50 Years of Age No dispute reported 06/30/2026 1253010186
Principal investigator 1 ModernaTX, Inc. $19,266.00 04/28/2025 Non-covered Recipient Entity
VALLEY CLINICAL TRIALS INC
A Study of mRNA-1010 Compared With a Licensed Influenza Vaccine in Adults ?50 Years of Age No dispute reported 06/30/2026 1253010190
Principal investigator 1 ModernaTX, Inc. $26,298.00 04/28/2025 Non-covered Recipient Entity
VALLEY CLINICAL TRIALS INC
A Study of mRNA-1010 Compared With a Licensed Influenza Vaccine in Adults ?50 Years of Age No dispute reported 06/30/2026 1253010224
Principal investigator 1 Amgen Inc. $23,327.23 04/23/2025 Non-covered Recipient Entity
FLOURISH RESEARCH
A Phase 3 Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy, Safety, and Tolerability of Maridebart Cafraglutide in Adult Participants With Type 2 Diabetes Mellitus Who Have Obesity or Are Overweight (MARITIME-2) No dispute reported 06/30/2026 1246641439
Principal investigator 1 Boehringer Ingelheim International GmbH $442.20 04/23/2025 Non-covered Recipient Entity
Valley Clinical Trials
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220784975
Principal investigator 1 Janssen Research & Development, LLC $8,983.00 04/23/2025 Non-covered Recipient Entity
Vly Clinic Trials
A Phase 3, Randomized, Double-Blind, Double-Dummy, Parallel Group, Active Controlled Study to Evaluate the Efficacy and Safety of Milvexian, an Oral Factor XIa Inhibitor, Versus Apixaban in Participants with Atrial Fibrillation No dispute reported 06/30/2026 1175174265
Principal investigator 1 Alnylam Pharmaceuticals Inc. $5,918.65 04/18/2025 Non-covered Recipient Entity
Valley Clinical Trials, Inc - Northridge - Flourish - PPDS
Zilebesiran as Add-on Therapy in Patients With High Cardiovascular Risk and Hypertension Not Adequately Controlled by Standard of Care Antihypertensive Medications (KARDIA-3) No dispute reported 06/30/2026 1215513487
Principal investigator 1 Novartis Pharmaceuticals Corporation $7,048.64 04/17/2025 Non-covered Recipient Entity
VALLEY CLINICAL TRIALS
A Randomized, Placebo-controlled, Parallel-group, Investigator- and Participant-blinded Phase 2a Study to Investigate the Efficacy, Safety, and Tolerability of DFV890 for Inflammatory Marker Reduction in Adult Participants With Coronary Heart Disease and No dispute reported 06/30/2026 1190313591
Principal investigator 1 Alnylam Pharmaceuticals Inc. $500.00 04/16/2025 Non-covered Recipient Entity
Valley Clinical Trials, Inc - Northridge - Flourish - PPDS
Zilebesiran as Add-on Therapy in Patients With High Cardiovascular Risk and Hypertension Not Adequately Controlled by Standard of Care Antihypertensive Medications (KARDIA-3) No dispute reported 06/30/2026 1215513452
Principal investigator 1 Alnylam Pharmaceuticals Inc. $1,000.00 04/16/2025 Non-covered Recipient Entity
Valley Clinical Trials, Inc - Northridge - Flourish - PPDS
Zilebesiran as Add-on Therapy in Patients With High Cardiovascular Risk and Hypertension Not Adequately Controlled by Standard of Care Antihypertensive Medications (KARDIA-3) No dispute reported 06/30/2026 1215513457
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $14,147.10 04/14/2025 Non-covered Recipient Entity
Valley Clinical Trials
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220817874
Principal investigator 1 Alnylam Pharmaceuticals Inc. $1,000.00 04/11/2025 Non-covered Recipient Entity
Valley Clinical Trials, Inc - Northridge - Flourish - PPDS
Zilebesiran as Add-on Therapy in Patients With High Cardiovascular Risk and Hypertension Not Adequately Controlled by Standard of Care Antihypertensive Medications (KARDIA-3) No dispute reported 06/30/2026 1215513461
Principal investigator 1 Alnylam Pharmaceuticals Inc. $2,775.85 04/01/2025 Non-covered Recipient Entity
Valley Clinical Trials, Inc - Northridge - Flourish - PPDS
Zilebesiran as Add-on Therapy in Patients With High Cardiovascular Risk and Hypertension Not Adequately Controlled by Standard of Care Antihypertensive Medications (KARDIA-3) No dispute reported 06/30/2026 1215513479
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 04/01/2025 Non-covered Recipient Entity
Valley Clinical Trials
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220784937
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 04/01/2025 Non-covered Recipient Entity
Valley Clinical Trials
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220784939
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 04/01/2025 Non-covered Recipient Entity
Valley Clinical Trials
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220784941
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 04/01/2025 Non-covered Recipient Entity
Valley Clinical Trials
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220784943
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 04/01/2025 Non-covered Recipient Entity
Valley Clinical Trials
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220784945
Principal investigator 1 Boehringer Ingelheim International GmbH $47.50 04/01/2025 Non-covered Recipient Entity
Valley Clinical Trials
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220784947
Principal investigator 1 Boehringer Ingelheim International GmbH $552.75 03/25/2025 Non-covered Recipient Entity
Valley Clinical Trials
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220784931
Principal investigator 1 Boehringer Ingelheim International GmbH $8.00 03/25/2025 Non-covered Recipient Entity
Valley Clinical Trials
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220784933
Principal investigator 1 ModernaTX, Inc. $26,298.00 03/24/2025 Non-covered Recipient Entity
VALLEY CLINICAL TRIALS INC
A Study of mRNA-1010 Compared With a Licensed Influenza Vaccine in Adults ?50 Years of Age No dispute reported 06/30/2026 1253010212
Principal investigator 1 ModernaTX, Inc. $17,606.16 03/24/2025 Non-covered Recipient Entity
VALLEY CLINICAL TRIALS INC
A Study of mRNA-1010 Compared With a Licensed Influenza Vaccine in Adults ?50 Years of Age No dispute reported 06/30/2026 1253010214
Principal investigator 1 ModernaTX, Inc. $15,490.42 03/24/2025 Non-covered Recipient Entity
VALLEY CLINICAL TRIALS INC
A Study of mRNA-1010 Compared With a Licensed Influenza Vaccine in Adults ?50 Years of Age No dispute reported 06/30/2026 1253010220
Principal investigator 1 Alnylam Pharmaceuticals Inc. $119.00 03/21/2025 Non-covered Recipient Entity
Valley Clinical Trials, Inc - Northridge - Flourish - PPDS
Zilebesiran as Add-on Therapy in Patients With High Cardiovascular Risk and Hypertension Not Adequately Controlled by Standard of Care Antihypertensive Medications (KARDIA-3) No dispute reported 06/30/2026 1215513379
Principal investigator 1 Janssen Research & Development, LLC $17,313.00 03/21/2025 Non-covered Recipient Entity
Vly Clinic Trials
A Phase 3, Randomized, Double-Blind, Double-Dummy, Parallel Group, Active Controlled Study to Evaluate the Efficacy and Safety of Milvexian, an Oral Factor XIa Inhibitor, Versus Apixaban in Participants with Atrial Fibrillation No dispute reported 06/30/2026 1175174513
Principal investigator 1 Janssen Research & Development, LLC $3,318.00 03/17/2025 Non-covered Recipient Entity
Vly Clinic Trials
A Study of Milvexian in Participants After a Recent Acute Coronary Syndrome (LIBREXIA-ACS) No dispute reported 06/30/2026 1175174695
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $38,144.70 03/14/2025 Non-covered Recipient Entity
Valley Clinical Trials
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220817872
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $500.00 03/13/2025 Non-covered Recipient Entity
Valley Clinical Trials
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220817868
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $800.00 03/13/2025 Non-covered Recipient Entity
Valley Clinical Trials
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220817870
Principal investigator 1 Alnylam Pharmaceuticals Inc. $6,409.70 03/12/2025 Non-covered Recipient Entity
Valley Clinical Trials, Inc - Northridge - Flourish - PPDS
Zilebesiran as Add-on Therapy in Patients With High Cardiovascular Risk and Hypertension Not Adequately Controlled by Standard of Care Antihypertensive Medications (KARDIA-3) No dispute reported 06/30/2026 1215513394
Principal investigator 1 Janssen Research & Development, LLC $593.97 03/07/2025 Non-covered Recipient Entity
VALLEY CLINICAL TRIALS INC
A Non-Interventional Survey Study on the Preferences of Patients with Atrial Fibrillation and Physicians Treating Atrial Fibrillation for Anticoagulant Treatment Outcomes No dispute reported 06/30/2026 1175346297
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 03/01/2025 Non-covered Recipient Entity
Valley Clinical Trials
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220784903
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 03/01/2025 Non-covered Recipient Entity
Valley Clinical Trials
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220784905
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 03/01/2025 Non-covered Recipient Entity
Valley Clinical Trials
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220784907
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 03/01/2025 Non-covered Recipient Entity
Valley Clinical Trials
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220784909
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 03/01/2025 Non-covered Recipient Entity
Valley Clinical Trials
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220784911
Principal investigator 1 Boehringer Ingelheim International GmbH $47.50 03/01/2025 Non-covered Recipient Entity
Valley Clinical Trials
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220784913
Principal investigator 1 ModernaTX, Inc. $28,468.88 02/27/2025 Non-covered Recipient Entity
VALLEY CLINICAL TRIALS INC
A Study of mRNA-1010 Compared With a Licensed Influenza Vaccine in Adults ?50 Years of Age No dispute reported 06/30/2026 1253010178
Principal investigator 1 ModernaTX, Inc. $19,562.40 02/27/2025 Non-covered Recipient Entity
VALLEY CLINICAL TRIALS INC
A Study of mRNA-1010 Compared With a Licensed Influenza Vaccine in Adults ?50 Years of Age No dispute reported 06/30/2026 1253010184
Principal investigator 1 ModernaTX, Inc. $18,993.00 02/27/2025 Non-covered Recipient Entity
VALLEY CLINICAL TRIALS INC
A Study of mRNA-1010 Compared With a Licensed Influenza Vaccine in Adults ?50 Years of Age No dispute reported 06/30/2026 1253010206
Principal investigator 1 Boehringer Ingelheim International GmbH $99.90 02/25/2025 Non-covered Recipient Entity
Valley Clinical Trials
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220784919
Principal investigator 1 Boehringer Ingelheim International GmbH $182.50 02/25/2025 Non-covered Recipient Entity
Valley Clinical Trials
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220784921
Principal investigator 1 Boehringer Ingelheim International GmbH $663.30 02/25/2025 Non-covered Recipient Entity
Valley Clinical Trials
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220784923
Principal investigator 1 Boehringer Ingelheim International GmbH $10.00 02/25/2025 Non-covered Recipient Entity
Valley Clinical Trials
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220784925
Principal investigator 1 Boehringer Ingelheim International GmbH $8.70 02/25/2025 Non-covered Recipient Entity
Valley Clinical Trials
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220784927
Principal investigator 1 Boehringer Ingelheim International GmbH $13.80 02/25/2025 Non-covered Recipient Entity
Valley Clinical Trials
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220784929
Principal investigator 1 Alnylam Pharmaceuticals Inc. $266.00 02/21/2025 Non-covered Recipient Entity
Valley Clinical Trials, Inc - Northridge - Flourish - PPDS
Zilebesiran as Add-on Therapy in Patients With High Cardiovascular Risk and Hypertension Not Adequately Controlled by Standard of Care Antihypertensive Medications (KARDIA-3) No dispute reported 06/30/2026 1215513337
Principal investigator 1 Alnylam Pharmaceuticals Inc. $471.80 02/21/2025 Non-covered Recipient Entity
Valley Clinical Trials, Inc - Northridge - Flourish - PPDS
Zilebesiran as Add-on Therapy in Patients With High Cardiovascular Risk and Hypertension Not Adequately Controlled by Standard of Care Antihypertensive Medications (KARDIA-3) No dispute reported 06/30/2026 1215513366
Principal investigator 1 Alnylam Pharmaceuticals Inc. $120.00 02/19/2025 Non-covered Recipient Entity
Valley Clinical Trials, Inc - Northridge - Flourish - PPDS
Zilebesiran as Add-on Therapy in Patients With High Cardiovascular Risk and Hypertension Not Adequately Controlled by Standard of Care Antihypertensive Medications (KARDIA-3) No dispute reported 06/30/2026 1215513313
Principal investigator 1 Alnylam Pharmaceuticals Inc. $119.00 02/19/2025 Non-covered Recipient Entity
Valley Clinical Trials, Inc - Northridge - Flourish - PPDS
Zilebesiran as Add-on Therapy in Patients With High Cardiovascular Risk and Hypertension Not Adequately Controlled by Standard of Care Antihypertensive Medications (KARDIA-3) No dispute reported 06/30/2026 1215513323
Principal investigator 1 Alnylam Pharmaceuticals Inc. $1,500.00 02/19/2025 Non-covered Recipient Entity
Valley Clinical Trials, Inc - Northridge - Flourish - PPDS
Zilebesiran as Add-on Therapy in Patients With High Cardiovascular Risk and Hypertension Not Adequately Controlled by Standard of Care Antihypertensive Medications (KARDIA-3) No dispute reported 06/30/2026 1215513346
Principal investigator 1 Janssen Research & Development, LLC $15,731.00 02/19/2025 Non-covered Recipient Entity
Vly Clinic Trials
A Phase 3, Randomized, Double-Blind, Double-Dummy, Parallel Group, Active Controlled Study to Evaluate the Efficacy and Safety of Milvexian, an Oral Factor XIa Inhibitor, Versus Apixaban in Participants with Atrial Fibrillation No dispute reported 06/30/2026 1175174466
Principal investigator 1 Alnylam Pharmaceuticals Inc. $60.00 02/14/2025 Non-covered Recipient Entity
Valley Clinical Trials, Inc - Northridge - Flourish - PPDS
Zilebesiran as Add-on Therapy in Patients With High Cardiovascular Risk and Hypertension Not Adequately Controlled by Standard of Care Antihypertensive Medications (KARDIA-3) No dispute reported 06/30/2026 1215513329
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $2,158.20 02/14/2025 Non-covered Recipient Entity
Valley Clinical Trials
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220817852
Principal investigator 1 Alnylam Pharmaceuticals Inc. $180.00 02/07/2025 Non-covered Recipient Entity
Valley Clinical Trials, Inc - Northridge - Flourish - PPDS
Zilebesiran as Add-on Therapy in Patients With High Cardiovascular Risk and Hypertension Not Adequately Controlled by Standard of Care Antihypertensive Medications (KARDIA-3) No dispute reported 06/30/2026 1215513349
Principal investigator 1 Alnylam Pharmaceuticals Inc. $1,547.00 02/07/2025 Non-covered Recipient Entity
Valley Clinical Trials, Inc - Northridge - Flourish - PPDS
Zilebesiran as Add-on Therapy in Patients With High Cardiovascular Risk and Hypertension Not Adequately Controlled by Standard of Care Antihypertensive Medications (KARDIA-3) No dispute reported 06/30/2026 1215513354
Principal investigator 1 Alnylam Pharmaceuticals Inc. $120.00 02/07/2025 Non-covered Recipient Entity
Valley Clinical Trials, Inc - Northridge - Flourish - PPDS
Zilebesiran as Add-on Therapy in Patients With High Cardiovascular Risk and Hypertension Not Adequately Controlled by Standard of Care Antihypertensive Medications (KARDIA-3) No dispute reported 06/30/2026 1215513370
Principal investigator 1 Janssen Research & Development, LLC $1,316.00 02/07/2025 Non-covered Recipient Entity
Vly Clinic Trials
A Phase 3, Randomized, Double-Blind, Double-Dummy, Parallel Group, Active Controlled Study to Evaluate the Efficacy and Safety of Milvexian, an Oral Factor XIa Inhibitor, Versus Apixaban in Participants with Atrial Fibrillation No dispute reported 06/30/2026 1175174894
Principal investigator 1 Eli Lilly and Company $29,386.00 02/04/2025 Non-covered Recipient Entity
VALLEY CLINICAL TRIALS INC
A STUDY OF LY3556050 IN ADULT PARTICIPANTS WITH DIABETIC PERIPHERAL NEUROPATHIC PAIN No dispute reported 06/30/2026 1187893534
Principal investigator 1 Alnylam Pharmaceuticals Inc. $3,236.60 02/03/2025 Non-covered Recipient Entity
Valley Clinical Trials, Inc - Northridge - Flourish - PPDS
Zilebesiran as Add-on Therapy in Patients With High Cardiovascular Risk and Hypertension Not Adequately Controlled by Standard of Care Antihypertensive Medications (KARDIA-3) No dispute reported 06/30/2026 1215513398
Principal investigator 1 Alnylam Pharmaceuticals Inc. $2,962.90 02/03/2025 Non-covered Recipient Entity
Valley Clinical Trials, Inc - Northridge - Flourish - PPDS
Zilebesiran as Add-on Therapy in Patients With High Cardiovascular Risk and Hypertension Not Adequately Controlled by Standard of Care Antihypertensive Medications (KARDIA-3) No dispute reported 06/30/2026 1215513403
Principal investigator 1 Alnylam Pharmaceuticals Inc. $2,938.40 02/03/2025 Non-covered Recipient Entity
Valley Clinical Trials, Inc - Northridge - Flourish - PPDS
Zilebesiran as Add-on Therapy in Patients With High Cardiovascular Risk and Hypertension Not Adequately Controlled by Standard of Care Antihypertensive Medications (KARDIA-3) No dispute reported 06/30/2026 1215513407
Principal investigator 1 Alnylam Pharmaceuticals Inc. $1,873.20 02/03/2025 Non-covered Recipient Entity
Valley Clinical Trials, Inc - Northridge - Flourish - PPDS
Zilebesiran as Add-on Therapy in Patients With High Cardiovascular Risk and Hypertension Not Adequately Controlled by Standard of Care Antihypertensive Medications (KARDIA-3) No dispute reported 06/30/2026 1215513411
Principal investigator 1 Alnylam Pharmaceuticals Inc. $8,058.05 02/03/2025 Non-covered Recipient Entity
Valley Clinical Trials, Inc - Northridge - Flourish - PPDS
Zilebesiran as Add-on Therapy in Patients With High Cardiovascular Risk and Hypertension Not Adequately Controlled by Standard of Care Antihypertensive Medications (KARDIA-3) No dispute reported 06/30/2026 1215513415
Principal investigator 1 Alnylam Pharmaceuticals Inc. $363.70 02/03/2025 Non-covered Recipient Entity
Valley Clinical Trials, Inc - Northridge - Flourish - PPDS
Zilebesiran as Add-on Therapy in Patients With High Cardiovascular Risk and Hypertension Not Adequately Controlled by Standard of Care Antihypertensive Medications (KARDIA-3) No dispute reported 06/30/2026 1215513419
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 02/01/2025 Non-covered Recipient Entity
Valley Clinical Trials
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220784889
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 02/01/2025 Non-covered Recipient Entity
Valley Clinical Trials
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220784891
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 02/01/2025 Non-covered Recipient Entity
Valley Clinical Trials
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220784893
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 02/01/2025 Non-covered Recipient Entity
Valley Clinical Trials
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220784895
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 02/01/2025 Non-covered Recipient Entity
Valley Clinical Trials
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220784897
Principal investigator 1 Boehringer Ingelheim International GmbH $86.00 02/01/2025 Non-covered Recipient Entity
Valley Clinical Trials
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220784899
Principal investigator 1 Boehringer Ingelheim International GmbH $47.50 02/01/2025 Non-covered Recipient Entity
Valley Clinical Trials
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220784901
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $24.00 01/31/2025 Non-covered Recipient Entity
Valley Clinical Trials
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220817854
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $16.00 01/31/2025 Non-covered Recipient Entity
Valley Clinical Trials
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220817856
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $76.00 01/31/2025 Non-covered Recipient Entity
Valley Clinical Trials
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220817858
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $8.00 01/31/2025 Non-covered Recipient Entity
Valley Clinical Trials
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220817860
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $16.00 01/31/2025 Non-covered Recipient Entity
Valley Clinical Trials
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220817862
Principal investigator 1 Eli Lilly and Company $195.00 01/31/2025 Non-covered Recipient Entity
MEHRDAD KEVIN ARIANI MD
A STUDY OF LY3556050 IN ADULT PARTICIPANTS WITH DIABETIC PERIPHERAL NEUROPATHIC PAIN No dispute reported 06/30/2026 1187884938
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $922.20 01/29/2025 Non-covered Recipient Entity
Valley Clinical Trials
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220817866
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $24,781.50 01/28/2025 Non-covered Recipient Entity
Valley Clinical Trials
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220817864
Principal investigator 1 Boehringer Ingelheim International GmbH $876.00 01/27/2025 Non-covered Recipient Entity
Valley Clinical Trials
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220784915
Principal investigator 1 Boehringer Ingelheim International GmbH $24.36 01/27/2025 Non-covered Recipient Entity
Valley Clinical Trials
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220784917
Principal investigator 1 ModernaTX, Inc. $8,373.20 01/27/2025 Non-covered Recipient Entity
VALLEY CLINICAL TRIALS INC
A Study of mRNA-1010 Compared With a Licensed Influenza Vaccine in Adults ?50 Years of Age No dispute reported 06/30/2026 1253010202
Principal investigator 1 ModernaTX, Inc. $20,629.44 01/27/2025 Non-covered Recipient Entity
VALLEY CLINICAL TRIALS INC
A Study of mRNA-1010 Compared With a Licensed Influenza Vaccine in Adults ?50 Years of Age No dispute reported 06/30/2026 1253010208
Principal investigator 1 ModernaTX, Inc. $26,298.00 01/27/2025 Non-covered Recipient Entity
VALLEY CLINICAL TRIALS INC
A Study of mRNA-1010 Compared With a Licensed Influenza Vaccine in Adults ?50 Years of Age No dispute reported 06/30/2026 1253010216
Principal investigator 1 ModernaTX, Inc. $54,137.20 01/27/2025 Non-covered Recipient Entity
VALLEY CLINICAL TRIALS INC
A Study of mRNA-1010 Compared With a Licensed Influenza Vaccine in Adults ?50 Years of Age No dispute reported 06/30/2026 1253010222
Principal investigator 1 Janssen Research & Development, LLC $897.00 01/22/2025 Non-covered Recipient Entity
Vly Clinic Trials
A Study of Milvexian in Participants After a Recent Acute Coronary Syndrome (LIBREXIA-ACS) No dispute reported 06/30/2026 1175174456
Principal investigator 1 Janssen Research & Development, LLC $23,902.00 01/22/2025 Non-covered Recipient Entity
Vly Clinic Trials
A Phase 3, Randomized, Double-Blind, Double-Dummy, Parallel Group, Active Controlled Study to Evaluate the Efficacy and Safety of Milvexian, an Oral Factor XIa Inhibitor, Versus Apixaban in Participants with Atrial Fibrillation No dispute reported 06/30/2026 1175174611
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $22,346.10 01/20/2025 Non-covered Recipient Entity
Valley Clinical Trials
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220817848
Principal investigator 1 ModernaTX, Inc. $1,092.00 01/17/2025 Non-covered Recipient Entity
VALLEY CLINICAL TRIALS INC
A Study of mRNA-1010 Compared With a Licensed Influenza Vaccine in Adults ?50 Years of Age No dispute reported 06/30/2026 1253010194
Principal investigator 1 ModernaTX, Inc. $14,112.21 01/17/2025 Non-covered Recipient Entity
VALLEY CLINICAL TRIALS INC
A Study of mRNA-1010 Compared With a Licensed Influenza Vaccine in Adults ?50 Years of Age No dispute reported 06/30/2026 1253010210
Principal investigator 1 Eli Lilly and Company $749.05 01/09/2025 Non-covered Recipient Entity
VALLEY CLINICAL TRIALS INC
A STUDY OF DONANEMAB VERSUS PLACEBO IN PARTICIPANTS AT RISK FOR COGNITIVE AND FUNCTIONAL DECLINE OF ALZHEIMER'S DISEASE No dispute reported 06/30/2026 1187890988
Principal investigator 1 Alnylam Pharmaceuticals Inc. $1,746.20 01/08/2025 Non-covered Recipient Entity
Valley Clinical Trials, Inc - Northridge - Flourish - PPDS
Zilebesiran as Add-on Therapy in Patients With High Cardiovascular Risk and Hypertension Not Adequately Controlled by Standard of Care Antihypertensive Medications (KARDIA-3) No dispute reported 06/30/2026 1215513386
Principal investigator 1 Alnylam Pharmaceuticals Inc. $70.00 01/08/2025 Non-covered Recipient Entity
Valley Clinical Trials, Inc - Northridge - Flourish - PPDS
Zilebesiran as Add-on Therapy in Patients With High Cardiovascular Risk and Hypertension Not Adequately Controlled by Standard of Care Antihypertensive Medications (KARDIA-3) No dispute reported 06/30/2026 1215513390
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $1,114.80 01/07/2025 Non-covered Recipient Entity
Valley Clinical Trials
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220817850
Principal investigator 1 Eli Lilly and Company $20,814.00 01/07/2025 Non-covered Recipient Entity
VALLEY CLINICAL TRIALS INC
A STUDY OF DONANEMAB VERSUS PLACEBO IN PARTICIPANTS AT RISK FOR COGNITIVE AND FUNCTIONAL DECLINE OF ALZHEIMER'S DISEASE No dispute reported 06/30/2026 1187891614
Principal investigator 1 Janssen Research & Development, LLC $157.00 01/06/2025 Non-covered Recipient Entity
Vly Clinic Trials
A Phase 3, Randomized, Double-Blind, Double-Dummy, Parallel Group, Active Controlled Study to Evaluate the Efficacy and Safety of Milvexian, an Oral Factor XIa Inhibitor, Versus Apixaban in Participants with Atrial Fibrillation No dispute reported 06/30/2026 1175174314
Principal investigator 1 AstraZeneca Pharmaceuticals LP $5,000.00 01/03/2025 Non-covered Recipient Entity
VALLEY CLINICAL TRIALS
a phase 3,global,randomized,modified double blind,placebo controlled,study to evaluate the efficacy,immunogenicity,and safety of IVX A12,a respiratory syncytial virus RSV and human metapneumovirus hMPV virus like particle VLP vaccine in adults 60 years of age and older No dispute reported 06/30/2026 1185537153
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 01/01/2025 Non-covered Recipient Entity
Valley Clinical Trials
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220784879
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 01/01/2025 Non-covered Recipient Entity
Valley Clinical Trials
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220784881
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 01/01/2025 Non-covered Recipient Entity
Valley Clinical Trials
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220784883
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 01/01/2025 Non-covered Recipient Entity
Valley Clinical Trials
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220784885
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 01/01/2025 Non-covered Recipient Entity
Valley Clinical Trials
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220784887
Principal investigator 1 Boehringer Ingelheim International GmbH $47.50 01/01/2025 Non-covered Recipient Entity
Valley Clinical Trials
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220784935